{"id": "279346", "url": "https://fevir.net/resources/Group/279346", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"], "versionId": "11", "lastUpdated": "2025-03-15T21:00:24.258Z"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\">[No data.]</div>", "status": "empty"}, "title": "ConceptualCohortDefinition: T2DM-specific criteria", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "ConceptualCohortDefinition: T2DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279346. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/279346. Computable resource at: https://fevir.net/resources/Group/279346#json."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "279346", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "resourceType": "Group", "characteristic": [{"code": {"coding": [{"code": "64572001", "system": "http://snomed.info/sct", "display": "Disease (disorder)"}]}, "method": [{"text": "based on the World Health Organization (WHO) diagnostic criteria"}], "exclude": false, "description": "Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria", "valueCodeableConcept": {"coding": [{"code": "44054006", "system": "http://snomed.info/sct", "display": "Diabetes mellitus type 2 (disorder)"}]}}, {"code": {"text": "Medication exposure"}, "exclude": false, "description": "Have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine", "durationDuration": {"code": "a", "unit": "years", "value": 1, "system": "http://unitsofmeasure.org", "comparator": ">="}, "valueCodeableConcept": {"text": "Daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs)\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"}}, {"code": {"coding": [{"code": "397669002", "system": "http://snomed.info/sct", "display": "Age"}]}, "timing": [{"contextCode": {"coding": [{"code": "182771004", "system": "http://snomed.info/sct", "display": "Informed consent for procedure"}]}, "offsetDuration": {"value": 0}}], "exclude": false, "valueRange": {"low": {"code": "a", "unit": "years", "value": 20, "system": "http://unitsofmeasure.org"}, "high": {"code": "a", "unit": "years", "value": 70, "system": "http://unitsofmeasure.org"}}, "description": "Are between 20 and 70 years old at the time of informed consent"}, {"code": {"coding": [{"code": "39156-5", "system": "http://loinc.org", "display": "Body mass index (BMI) [Ratio]"}]}, "timing": [{"contextCode": {"text": "screening"}, "offsetDuration": {"value": 0}}], "exclude": false, "valueRange": {"low": {"code": "kg/m2", "unit": "kilogram per square meter (kg/m2)", "value": 18.5, "system": "http://unitsofmeasure.org"}, "high": {"code": "kg/m2", "unit": "kilogram per square meter (kg/m2)", "value": 35, "system": "http://unitsofmeasure.org"}}, "description": "Have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"}], "combinationMethod": "all-of"}